marijuana stocks

GrowBLOX Sciences Announces Patent Filings for Its Proprietary Process to Create Uniform Reproducible Cannabis Extracts

 GrowBLOX Sciences, Inc., (OTCQB:GBLX) On October 2nd, GBLX filed its third strategic patent in the series that protects its proprietary, automated, growth chambers for propagating, growing and curing medical botanicals. Previously filed patents had focused on the method and apparatus that comprises the original GrowBLOX chambers.

The new patent covers the TissueBLOX(TM), VegBLOX(TM), GrowBLOX(TM), and CureBLOX(TM), which form a comprehensive growth system characterized by real-time monitoring, managing and controlling the operation of the integrated system based upon real-time sensed parameters.

According to the new patent application, the GrowBLOX(TM) Technology Suite is “an integrated plant cultivation system for optimizing, promoting and enhancing the rapid growth of a least one plant during one or more stages of its development cycle.”

Dr. Andrea Small-Howard, Chief Science Officer, averred, “Our new patent addresses the creation of standardized cannabis extracts within the comprehensive GrowBLOX system. These extracts are critical for predictable patient relief and use in clinical trials in our dispensary system.”

Primary biological applications of the comprehensive GrowBLOX(TM) technology suite now include patent protection for the following:

a) The plant is capable of providing plant-based medical solutions to combat at least one clinically diagnosed health issue.
b) The cultivation and processing protocols provide uniform medicinal extracts independent of the location of production, season or personnel.
c) The medicinal plants are produced to provide plant extracts that are of reproducible chemical composition and purity.
d) Medicinal plants are produced in aseptic conditions.

Craig Ellins, Chief Executive Officer, said, “With the filing of this latest application, we enable the world to see not only what our technology can do for the development of pharmaceutical grade medical cannabis, but also what we can do to standardize many plant-based therapeutic agents. Today, many such therapeutic agents can be produced in quantity only by inferior techniques such as recombinant expression systems in yeast or bacteria. We believe that soon our technology will help to remedy that problem by standardizing clinical therapies formed from complex plant-based mixtures.”

“THE GROWBLOX PRODUCTS ARE MANUFACTURED UNDER ONE OR MORE OF THE FOLLOWING U.S.P.T.O NUMBERS: 14821742, 14821743 AND 14873413 AND PENDING PATENTS”

About GrowBLOX Sciences, Inc.

GrowBLOX Sciences, Inc. (GBLX) is a biopharmaceutical research and development company focused on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. The Company has leading technology and cannabis industry processes, with a “big” data-driven clinical research and development loop to bring relief to patients in communities across the country. Through our GBS PR subsidiary, we are developing and globally distributing our GrowBLOX(TM) suite of cultivation and growing chambers. To learn more about GrowBLOX Sciences, Inc., go to: https://growblox.com

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note: Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as presently constituted.

GrowBLOX is a registered trademark of GrowBLOX Sciences, Inc.

Contact Information

Corporate:

GrowBLOX Sciences, Inc.,
6450 Cameron Street, Suite 110A, Las Vegas, NV 89118
866-721-0297
Craig Ellins, CEO
Andrea Small Howard, Chief Science Officer
craig@gbsciences.com
andrea@gbsciences.com
https://growblox.com

Investors:

Hayden IR
hart@haydenir.com
917-658-7878

SOURCE: GrowBLOX Sciences, Inc.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

1933 Industries (TGIF) (TGIFF) Reports Fourth Quarter and Annual Financial Results for Fiscal Year 2019

The Company reports revenues of $5.2M in Q4 and $18.1M for the…